|
AU2013205946A1
|
|
Salicylate conjugates useful for treating metabolic disorders
|
|
WO2013037984A1
|
|
Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
|
|
EP2755645A1
|
|
Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
|
|
WO2012080371A1
|
|
New thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
|
|
AU2010224866A1
|
|
Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
|
|
AU2010224867A1
|
|
Combination therapies for treating metabolic disorders
|
|
CN103251631A
|
|
Salicylate conjugates useful for treating metabolic disorders
|
|
WO2007131996A1
|
|
Meta-xylylenediamine vanadate salts
|
|
US2007066646A1
|
|
Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
|
|
EP1827463A1
|
|
Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia
|
|
CN101087601A
|
|
Compounds for inhibiting copper-containing amine oxidases and uses thereof
|
|
WO2006003189A1
|
|
Arylalkylamine vanadium (v) salts for the treatment and/or prevention of diabetes mellitus
|
